财务数据和关键指标变化 - 公司收入同比增长20%,达到3.12亿美元 [9] - 调整后EBITDA同比增长103%,达到2900万美元 [19] - 每次就诊总收入同比增长4%,达到159美元 [17] - 中心利润率同比增长34%,达到9800万美元 [18] 各条业务线数据和关键指标变化 - 公司现有近7000名员工医生,同比增长14% [9] - 过去5个季度,医生增长100%来自内部 [9] - 患者满意度指数为86,平均谷歌评分为4.6分 [10] 各个市场数据和关键指标变化 - 公司在33个州开展业务 [12] 公司战略和发展方向及行业竞争 - 公司正在优化运营模式,提升前台支持和临床领导力,以改善患者和医生体验 [12] - 公司正在与医保公司建立合作伙伴关系,讨论费率、管理条款和价值支付模式 [30][31] - 行业内对虚拟诊疗和实体诊疗的需求有所变化,公司正在调整应对 [37][39] 管理层对经营环境和未来前景的评论 - 公司有信心全年实现正自由现金流 [21][57] - 公司有信心在2025年实现两位数利润率、中高单位数收入增长和正自由现金流 [57] 其他重要信息 - 公司正在优化数字化工具,提升运营效率和患者体验 [11][12] - 公司将在下半年加大投资,以更好地实现2025年目标 [41][42]

Reimagining Mental Health Q2 2024 Earnings Presentation • August 8, 2024 Forward-Looking Statements DISCLAIMERS Cautionary Note Regarding Forward-Looking Statements This presentation and related oral statements, including during any question and answer portion of the presentation, contain forward-looking statements about LifeStance Health Group, Inc. and its subsidiaries ("LifeStance") and the industry in which LifeStance operates, including statements regarding: full-year and third quarter guidance and man ...

LifeStance Health Group (LFST) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.29%. A quarter ago, it was expected that this outpatient mental health services provider would post a loss of $0.09 per share when it actually produced a loss of $0.06, delivering a surprise of 33.33%.Over the l ...

财务表现 - 收入同比增长20%至3.123亿美元[3] - 总收入为6.13亿美元，同比增长19.6%[20] - 运营成本为6.45亿美元，同比增长8.5%[20] - 经营亏损为3,272万美元，同比减亏49.6%[20] - 净亏损为4,437万美元，同比减亏44.4%[21] - 经营活动产生的现金流为2,222万美元，同比增加[23] 盈利能力 - 中心利润率增长34%至0.978亿美元，占总收入的31.3%[5] - 中心利润率为31.4%，同比提升[24] - 调整后EBITDA增长103%至0.286亿美元，占总收入的9.2%[5,6] - 调整后EBITDA为5,626万美元，同比增长132.8%[26] 业务发展 - 临床医生人数增加14%至6,984人[3] - 第二季度就诊量增加15%至200万次[3] - 预计2024年全年收入为12亿美元至12.42亿美元，中心利润为3.63亿美元至3.83亿美元，调整后EBITDA为0.9亿美元至1亿美元[9] - 预计2024年第三季度收入为2.9亿美元至3.1亿美元，中心利润为0.83亿美元至0.95亿美元，调整后EBITDA为0.15亿美元至0.21亿美元[9] 资产负债 - 2024年上半年经营活动产生的现金流为0.222亿美元，第二季度为0.441亿美元[8] - 截至2024年6月30日，现金余额为0.87亿美元，长期债务净额为2.795亿美元[8] 非经常性费用 - 股票激励费用为4,513万美元[26] - 并购交易费用为79.2万美元[26] - 诉讼费用为82.9万美元[26] - 诉讼费用仅包括那些被认为是非经常性和非日常业务的费用，包括证券集体诉讼、隐私集体诉讼和薪酬模式集体诉讼[2] - 战略举措包括与最近重大扩张相关的多阶段系统升级的直接费用，包括人力资源管理、医生认证和入职流程以及可扩展的电子健康资源系统[3] - 房地产优化和重组费用包括现金费用和非现金费用，与公司房地产优化举措相关，包括某些资产减值和处置成本、提前终止租约的某些收益和损失以及退出和处置费用[4] - 已资本化的云计算软件实施成本的摊销计入一般和管理费用[5] - 收购中心的整合费用和前所有者费用不反映中心的经常性运营费用[6] - 公司在第二季度完成了二次公开募股，主要包括资本市场咨询、咨询、会计和法律费用[1]

Shares of LifeStance Health Group (LFST) have gained 13.7% over the past four weeks to close the last trading session at $5.58, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $8.64 indicates a potential upside of 54.8%.The mean estimate comprises seven short-term price targets with a standard deviation of $0.94. While the lowest estimate of $7 indicates a 25.5% increase from th ...

FOCUS combines a precision blend of citicoline, tyrosine and pure lion's mane mushroom to deliver superior clarity of cognition and improved memory. TORONTO, July 26, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, is pleased to announce that its U.S. biosciences subsidiary Mikra Cellular Sciences ...

LifeStance Health Group (LFST) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by t ...

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF) a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, today announced that it has closed a non-brokered priva ...

Shares of LifeStance Health Group (LFST) have gained 1.3% over the past four weeks to close the last trading session at $5.49, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $8.64 indicates a potential upside of 57.4%.The mean estimate comprises seven short-term price targets with a standard deviation of $0.94. While the lowest estimate of $7 indicates a 27.5% increase from the ...

TORONTO, July 08, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, reports that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. (“Mikra”) has filed a Natural Health Product License Application (“PLA”) with Health Canada, seeking a Natural Product Number (“NPN”) for its best-selling ce ...